ChristineMPellegrinoMD

PubMed

• 16 citations
  Phase I Trial of Veliparib, a Poly ADP Ribose Polymerase Inhibitor, Plus Metronomic Cyclophosphamide in Metastatic HER2-negative Breast Cancer.
  Jesus Anampa, Alice P. Chen, John J. Wright, Margi Patel, Christine M. Pellegrino, Karen Fehn, Joseph A. Sparano, Eleni Andreopoulou> ;Clinical Breast Cancer. 2017 Sep 1
• 15 citations
  A Phase I/II study of suberoylanilide hydroxamic acid (SAHA) in combination with trastuzumab (Herceptin) in patients with advanced metastatic and/or local chest wall r...
  Lori J. Goldstein, Fengmin Zhao, Molin Wang, Ramona F. Swaby, Joseph A. Sparano, Neal J. Meropol, Kapil N. Bhalla, Christine M. Pellegrino, R. Katherine Alpaugh, Carla...> ;Breast Cancer Research and Treatment. 2017 Jun 16
• 44 citations
  A phase I-II study of the histone deacetylase inhibitor vorinostat plus sequential weekly paclitaxel and doxorubicin-cyclophosphamide in locally advanced breast cancer
  Yifan Tu, Dawn L. Hershman, Kapil N. Bhalla, Warren Fiskus, Christine M. Pellegrino, Eleni Andreopoulou, DF Makower, Kevin Kalinsky, Karen Fehn, Susan Fineberg, Abdiss...> ;Breast Cancer Research and Treatment. 2014 Jun 6
• 16 citations
  Phase I–II study of the farnesyl transferase inhibitor tipifarnib plus sequential weekly paclitaxel and doxorubicin–cyclophosphamide in HER2/neu-negative inflammatory ...
  Eleni Andreopoulou, Ivette Vigoda, Vicente Valero, Dawn L. Hershman, George Raptis, Linda T. Vahdat, Hyo S. Han, John J. Wright, Christine M. Pellegrino, Massimo Crist...> ;Breast Cancer Research and Treatment. 2013 Sep 26
• 43 citations
  Eribulin mesylate versus ixabepilone in patients with metastatic breast cancer: a randomized Phase II study comparing the incidence of peripheral neuropathy
  Linda T. Vahdat, Agustin A. Garcia, Charles L. Vogel, Christine M. Pellegrino, Deborah Lindquist, Nicholas Iannotti, Prashanth Gopalakrishna, Joseph A. Sparano> ;Breast Cancer Research and Treatment. 2013 Jul 23
• 60 citations
  Phase I–II study of vorinostat plus paclitaxel and bevacizumab in metastatic breast cancer: evidence for vorinostat-induced tubulin acetylation and Hsp90 inhibition in...
  Bhuvaneswari Ramaswamy, Warren Fiskus, B. Cohen, Christine M. Pellegrino, Dawn L. Hershman, E. Chuang, Thehang Luu, George Somlo, Matthew Bidwell Goetz, Ramona F. Swab...> ;Breast Cancer Research and Treatment. 2012 Apr 1
• 99 citations
  Phase II trial of saracatinib (AZD0530), an oral SRC-inhibitor for the treatment of patients with hormone receptor-negative metastatic breast cancer.
  Ayca Gucalp, Joseph A. Sparano, James F. Caravelli, Jean T. Santamauro, Sujata Patil, A. Abbruzzi, Christine M. Pellegrino, J. Bromberg, Chau T. Dang, Maria Theodoulou...> ;Clinical Breast Cancer. 2011 Oct 1
• 52 citations
  Phase II trial of tipifarnib plus neoadjuvant doxorubicin-cyclophosphamide in patients with clinical stage IIB-IIIC breast cancer.
  Joseph A. Sparano, Stacy Moulder, Aslamuzzaman Kazi, Domenico Coppola, Abdissa Negassa, Linda T. Vahdat, Tianhong Li, Christine M. Pellegrino, Susan Fineberg, Pamela N...> ;Clinical Cancer Research. 2009 Apr 15
• 62 citations
  Targeted inhibition of farnesyltransferase in locally advanced breast cancer: a phase I and II trial of tipifarnib plus dose-dense doxorubicin and cyclophosphamide.
  Joseph A. Sparano, Stacy L. Moulder, Aslamuzzaman Kazi, Linda T. Vahdat, Tianhong Li, Christine M. Pellegrino, Pamela N. Munster, Mokenge P. Malafa, David I. Lee, Shir...> ;Journal of Clinical Oncology. 2006 Jul 1
• 57 citations
  Molecular identification and expression of erythroid K:Cl cotransporter in human and mouse erythroleukemic cells.
  Christine M. Pellegrino, Anne C. Rybicki, Sylvia Musto, Ronald L. Nagel, Robert S. Schwartz> ;Blood Cells, Molecules & Diseases. 1998 Mar 1
• Join now to see all